Characterization of mucins in human lacrimal sac and nasolacrimal duct

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 5, 2003, Pages 1807-1813

  Paulsen, Friedrich P ^a   Corfield, Anthony P ^b   Hinz, Margitta ^c   Hoffmann, Werner ^c   Schaudig, Ulrich ^d   Thale, Andreas B ^a   Berry, Monica ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; MESSENGER RNA; MUCIN; MUCIN 1; MUCIN 2; MUCIN 4; MUCIN 5B; MUCIN 6; MUCIN 7; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLUMNAR EPITHELIUM; CONJUNCTIVA; CONTROLLED STUDY; DISEASE ASSOCIATION; EPIPHORA; EPITHELIUM CELL; FEMALE; GOBLET CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LACRIMAL APPARATUS; LACRIMAL DUCT; LACRIMAL SAC; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALIVARY GLAND; STENOSIS;

ADULT; AGED; AGED, 80 AND OVER; DACRYOCYSTORHINOSTOMY; DNA, COMPLEMENTARY; EPITHELIAL CELLS; FEMALE; GOBLET CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; LACRIMAL APPARATUS; LACRIMAL DUCT OBSTRUCTION; MALE; MIDDLE AGED; MUCINS; NASOLACRIMAL DUCT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER;

EID: 0037408379     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.02-0744     Document Type: Article

References (38)

1. Paulsen F, Thale A, Schaudig U. Ableitende Tränenwege und Trockenes Auge. Ophthalmologe. 2002;99:566-574.
2. Paulsen F. The human nasolacrimal ducts. Adv Anat Embryol Cell Biol. 2003;170:1-106.
3. Paulsen F, Thale A, Kohla G, et al. Functional anatomy of human lacrimal duct epithelium. Anat Embryol. 1998;198:1-12.
4. Thale A, Paulsen F, Kohla G, Schauer R, Rochels R, Tillmann B. Die ableitenden Tränenwege unter physiologischen und immunologischen Gesichtspunkten. Ophthalmologe. 2001;98:56-63.
5. Paulsen F, Hinz M, Schaudig U, Thale A, Hoffmann W. TFF-peptides in the human efferent tear ducts. Invest Ophthalmol Vis Sci. 2002;43:3359-3364.
6. Langer G, Jagla W, Behrens-Baumann W, Walter S, Hoffmann W. Secretory peptides TFF1 and TFF3 synthesized in human conjunctival goblet cells. Invest Ophthalmol Vis Sci. 1999;40:2220-2224.
7. Hoffmann W, Jagla W, Wiede A. Molecular medicine of TFF-peptides: from gut to brain. Histol Histopathol. 2001;16:319-334.
8. Jung HH, Lee JH, Kim YT, Lee SD, Park JH. Expression of mucin genes in chronic ethmoiditis. Am J Rhinol. 2000;14:163-170.
9. Xing PX, Tjandra JJ, Reynolds K, McLaughlin PJ, Purcell DF, McKenzie IF. Reactivity of anti-human milk fat globule antibodies with synthetic peptides. J Immunol. 1989;142:3503-3509.
10. Burchell J, Gendler S, Taylor-Papadimitriou J, et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 1987;47:5476-5482.
11. Taylor-Papadimitriou J, Peterson JA, Arklie J, Burchell J, Ceriani RL, Bodmer WF. Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer. 1981;28:17-21.
12. Burchell J, Taylor-Papadimitriou J. Antibodies to human milk fat globule molecules. Cancer Invest. 1989;7:53-61.
13. Wickström C, Davies JR, Eriksen GV, Veerman EC, Carlstedt I. MUC5B is a major gel-forming, oligomeric mucin from human salivary gland, respiratory tract and endocervix: identification of glycoforms and C-terminal cleavage. Biochem J. 1998;334:685-693.
14. Thornton DJ, Howard M, Khan N, Sheehan JK. Identification of two glycoforms of the MUC5B mucin in human respiratory mucus: evidence for a cysteine-rich sequence repeated within the molecule. J Biol Chem. 1997;272:9561-9566.
15. Lopez-Ferrer A, de Bolos C, Barranco C, et al. Role of fucosyltransferases in the association between apomucin and Lewis antigen expression in normal and malignant gastric epithelium. Gut. 2000; 47:349-356.
16. Wickstrom C, Christersson C, Davies JR, Carlstedt I. Macromolecular organization of saliva: identification of "insoluble" MUC5B assemblies and non-mucin proteins in the gel phase. Biochem J. 2000;351:421-428.
17. Paulsen FP, Thale AB, Hallmann UJ, Schaudig U, Tillmann BN. The cavernous body of the human efferent tear ducts: function in tear outflow mechanism. Invest Ophthalmol Vis Sci. 2000;41:965-970.
18. McKenzie RW, Jumblatt JE, Jumblatt MM. Quantification of MUC2 and MUC5AC transcripts in human conjunctiva. Invest Ophthalmol Vis Sci. 2000;41:703-708.
19. Bobek LA, Tsai H, Biesbrock AR, Levine MJ. Molecular cloning, sequence, and specificity of expression of the gene encoding the low molecular weight human salivary mucin (MUC7). J Biol Chem. 1993;268:20563-20569.
20. Watanabe H. Significance of mucin on ocular surface. Cornea. 2002;21(suppl 1):17-21.
21. Tabak LA. In defense of the oral cavity: structure, biosynthesis and function of salivary mucins. Annu Rev Physiol. 1995;57:547-564.
22. Gururaja TL, Ramasubbu N, Venugopalan P, Reddy MS, Ramalingam K, Levine MJ. Structural features of the human salivary mucin, MUC7. Glycoconj J. 1998;15:457-467.
23. Gururaja TL, Levine JH, Tran DT, et al. Candidacidal activity prompted by N-terminus histatin-like domain of human salivary mucin (MUC7)1. Biochim Biophys Acta. 1999;1431:107-119.
24. Baughan LW, Robertello FJ, Sarrett DC, Denny PA, Denny PC. Salivary mucin as related to oral Streptococcus mutans in elderly people. Oral Microbiol Immunol. 2000;15:10-14.
25. Liu B, Rayment SA, Gyurko C, Oppenheim FG, Offner GD, Troxler RF. The recombinant N-terminal region of human salivary mucin MG2 (MUC7) contains a binding domain for oral Streptococci and exhibits candidacidal activity. Biochem J. 2000;345:557-564.
26. Situ H, Bobek L. In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1. Antimicrob Agents Chemother. 2000;44:1485-1493.
27. Lin J, Tsuprun V, Kawano H, et al. Characterization of mucins in human middle ear and Eustachian tube. Am J Physiol. 2001;280: L1157-L1167.
28. Corfield AP, Carrington SD, Hicks SJ, Berry M, Ellingham RB. Ocular mucins: purification, metabolism and functions. Prog Retinal Eye Res. 1997;16:627-656.
29. Perra MT, Serra A, Sirigu P, Turno F. A histochemical and immunohistochemical study of certain defense mechanisms in the human lacrimal sac epithelium. Arch Histol Cytol. 1995;58:517-522.
30. Paulsen F, Paulsen J, Thale A, Tillmann B. Mucosa-associated lymphoid tissue (MALT) in the human efferent tear ducts. Virchows Arch. 2000;437:185-189.
31. Paulsen F, Pufe T, Schaudig U, et al. Detection of natural peptide antibiotics in human nasolacrimal ducts. Invest Ophthalmol Vis Sci. 2001;42:2157-2163.
32. Paulsen F, Pufe T, Schaudig U, et al. Protection of human efferent tear ducts by antimicrobial peptides. Adv Exp Med Biol. 2002;506:547-553.
33. Sirigu P, Maxia C, Puxeddu R, Zucca I, Piras F, Perra MT. The presence of a local immune system in the upper blind and lower part of the human nasolacrimal duct. Arch Histol Cytol. 2000;63:431-439.
34. Knop E, Knop N. Lacrimal drainage-associated lymphoid tissue (LDALT): a part of the human mucosal immune system. Invest Ophthalmol Vis Sci. 2001;42:566-574.
35. Busse H, Müller KM. Zur Entstehung der idiopathischen Dakryostenose. Klin Monatsbl Augenheilkd. 1977;170:627-632.
36. Linberg JV, McCormick SA. Primary acquired nasolacrimal duct obstruction: a clinical pathologic report and biopsy technique. Ophthalmology. 1986;93:1055-1063.
37. Mauriello JA, Palydowycz S, DeLuca J. Clinicopathologic study of lacrimal sac and nasal mucosa in 44 patients with complete acquired nasolacrimal duct obstruction. Ophthalmic Plast Reconstr Surg. 1992;8:13-21.
38. Paulsen F, Thale A, Maune S, Tillmann B. Primary acquired dacryostenosis: histopathology and pathophysiology. Ophthalmology. 2001;108:2329-2336.